Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Active Psoriatic Arthritis
NCT02798211Phase 4Completed
- Sponsor
- Novartis
- Start
- Jun 2016
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 4 trial of secukinumab in psoriatic arthritis (PsA), sponsored by Novartis. Started Jun 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02798211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02798211.